Skip to content

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07420751
Enrollment
18
Registered
2026-02-19
Start date
2026-02-19
Completion date
2026-08-06
Last updated
2026-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NF2-related Schwannomatosis

Keywords

NF2-SWN, Hearing Loss, Auto-captioning glasses, Augmented Reality, NF2, Neurofibromatosis Type II, Neurofibromatosis Type 2

Brief summary

The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population. Participants will be asked to: * Use the glasses at their discretion for 12 weeks * Report their feedback at 3 and 12 week timepoints via online surveys and remote qualitative interviews

Detailed description

Patients with NF2-related schwannomatosis (NF2-SWN) often experience progressive hearing loss. The nature of their hearing loss frequently hinders the use of surgical or drug interventions. Due to this, assistive hearing technology such as speech to text machines are commonplace in this population. New technology such as augmented reality (AR) auto-captioning glasses are gaining popularity among deafened and hard of hearing participants for their ability to overlay live captions onto see-through lenses. The goal of this study is to investigate the feasibility and acceptability of this technology in the NF2-SWN population. The investigators aim to achieve this goal by recruiting up to 20 adult participants with a diagnosis of NF2-SWN and a history of hearing loss to a single-arm, open pilot study. The participants will be provided with a pair of Captify auto-captioning glasses to use over a period of 12 weeks. The investigators will assess participant's use of and feedback of the device at a 3-week timepoint and at study completion. At baseline, the investigators will enroll participants and obtain informed consent to participate. Patient background information will be collected at baseline alongside a short qualitative interview. After three weeks, participants will complete select patient-reported questionnaires to assess their feedback. After 12 weeks, the participants will again perform final surveys and follow-up interview, and return the glasses to clinic.

Interventions

DEVICEAuto-captioning Glasses

Augmented reality glasses that overlay real time captioning on see-through lenses, allowing users to read what is being said out loud.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of NF2-SWN by 2022 revised criteria * Age 18 years or older at time of consent * Willing and able to sign informed consent * Access to a mobile phone with current operating software (i.e., iOS 16+ or Android 12+) and an internet connection * Does not require prescription glasses to communicate others (e.g. may use reading glasses or similar) * Resident of the U.S. * English-speaking

Exclusion criteria

* Current use of auto-captioning glasses

Design outcomes

Primary

MeasureTime frameDescription
System Usability Scale12 WeeksUsed to assess the usability of the auto-captioning glasses, scored from 0-100, with higher scores indicating higher usability.

Secondary

MeasureTime frameDescription
Modified Telehealth Usability Questionnaire (Satisfaction and Future Use Sub-scale)12 WeeksUsed to measure user satisfaction with the intervention, with individual items scored on a scale of 1-7 where higher numbers are more satisfactory; total score is an average of each item in the sub-scale
Self-Reported Device Use12 WeeksParticipants will be asked whether they have used the device in the prior week, we will report the frequency (n) and percentage (%) of participants who report positively.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORVanessa Merker, PhD

Massachusetts General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 26, 2026